Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

International Scientists' Network To Map Drug-Resistant Malaria
PTI/Hindu reports on the Worldwide Antimalarial Resistance Network (WWARN) - an "international network of malaria scientists," which will be "established to map the emergence of resistance" to malaria drugs and "guide global efforts to control and eradicate the disease." The goal of WWARN, which "will integrate the efforts of researchers, NGOs and public health experts in malaria-endemic areas around the world," is to provide "comprehensive and rigorous evidence" for policy makers, which will help them "select the best anti-malarial treatments and to formulate strategies to control the critical problem of resistance wherever it arises," PTI/Hindu writes.

Clinton Comments On Vacant USAID Administrator Post
"Secretary of State Hillary Clinton said Monday she is frustrated over the failure" to name a new head of the USAID, despite it being a priority for the administration, AFP/Google.com reports. "Clinton, addressing USAID staff who asked why there was no administrator and deputy six months into President Barack Obama"s administration, complained about what she called an increasingly burdensome vetting process," the news service writes (7/13).
News of the day
New Study Highlights Threat Of Resistance To Artemisinin-Based Anti-Malarial Drugs
Malaria parasites in western Cambodia have become resistant to artemisinin-based therapies, the first-line treatment for malaria, according to a study published in the New England Journal of Medicine. Resistance to the drugs makes them less effective and could eventually render them obsolete, putting millions of lives at risk.
Endocrinology

Results From Trials Of DHA In Alzheimer's Disease And Age-Related Cognitive Decline

Results from two large studies using DHA, an omega 3 fatty acid, were reported at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna. One of the trials was conducted by the Alzheimer"s Disease Cooperative Study (ADCS) supported by the U.S. National Institute on Aging (NIA), and the second by Martek Biosciences Corporation. The NIA trial lasted 18 months and was conducted in people with mild to moderate Alzheimer"s. Martek"s trial was six months, and was conducted in healthy people to see its effect on "age related cognitive decline" Both studies used Martek"s algal DHA. The results of the ADCS trial show no evidence for benefit in the studied population. The Martek trial showed a positive result on one test of memory and learning, but that study was in healthy older adultswith mild memory complaint, not people with Alzheimer"s or another dementia. The results need confirmation. "These two studies - and other recent Alzheimer"s therapy trials - raise the possibility that treatments for Alzheimer"s must be given very early in the disease for them to be truly effective," said William Thies, PhD, Chief Medical & Scientific Officer at the Alzheimer"s Association. "For that to happen, we need to get much better at early detection and diagnosis of Alzheimer"s." DHA (docosahexaenoic acid) is the most abundant omega 3 fatty acid in the brain. Previous animal studies and epidemiology in humans suggested that DHA may be beneficial in people with Alzheimer"s. The studies reported at ICAD 2009 were: -- Joseph Quinn, et al - A clinical trial of docosahexaenoic acid (DHA) for the treatment of Alzheimer"s disease. -- Karin Yurko-Mauro, et al - Results of the MIDAS Trial: Effects of Docosahexaenoic Acid on Physiological and Safety Parameters in Age-Related Cognitive Decline. The 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009) brings together more than 3,000 researchers from 70 countries to share groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer"s disease and related disorders. ICAD 2009 will be held in Vienna, Austria at Messe Wien Exhibition and CongressCenter from July 11-16. The Alzheimer"s Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer"s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer"s. For more information, visit www.alz.org. Alzheimer"s Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009